Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sound waves zap kidney fat to lower blood pressure

NCT ID NCT06018493

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed trial tested a new, noninvasive device that uses focused ultrasound to destroy a small amount of fat around the kidney. The goal was to lower blood pressure in people with mild hypertension who were not taking medication. 79 participants were randomly assigned to receive either the real ultrasound or a sham procedure, and their blood pressure was monitored over one to three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
focused power ultrasound device
What this could lead to
If successful, this could offer a noninvasive, drug-free option to lower blood pressure in people with mild hypertension.
What could go wrong
This is a small, early-stage trial with only 79 participants. The effects may be modest or not last long, and the procedure carries risks like tissue damage or temporary discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

79 people

The number who actually took part.

Started

Sep 2023

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individual with office systolic blood pressure (SBP) ≥ 140 mmHg and \<160 mmHg, and diastolic blood pressure\<100mmHg when not taking antihypertensive drugs for at least 1 month; 2. Individual with 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP≥130 mmHg; 3. The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm; 4. Individual is willing to sign the informed consent of the study. Exclusion Criteria: 1. Individual with office systolic blood pressure (SBP) ≥ 160 mmHg and/or office diastolic blood pressure(DBP)≥ 100mmHg; 2. Individual diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome); 3. Individuals with ≥ 3 cardiovascular risk factors (male\>55 years old, female\>65 years old; smoking or passive smoking; 2-hour postprandial blood glucose 7.8-11mmol/L and/or impaired fasting glucose (6.1-6.9mmol/L); LDL-C ≥ 3.4mmol/L (130mg/dl), HDL-C\<1.0mmol/L (40mg/dl) or TC ≥ 5.2mmol/L (200mg/dl); Family history of early onset of cardiovascular disease, age of onset of first degree relatives\<50 years old; Abdominal obesity, waist circumference: male≥90cm, female≥85cm or BMI≥28kg/m2) or hypertensive target organ damage; 4. Individuals taking other medications that may affect blood pressure (such as glucocorticoids); 5. Individual with history of kidney or kidney surrounding tissue surgery; 6. Individuals with impairment of liver or kidney function (ALT, AST or creatinine greater than 2 times of the upper limit of normal reference); 7. Individual with myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment; 8. Individual with type 1 diabetes or uncontrolled type 2 diabetes; 9. Individual with uncontrolled thyroid dysfunction; 10. Individual with urinary calculi or hematuria; 11. Individual with atrial fibrillation; 12. Individual with severe structural heart disease (e.g. valvular heart disease, cardiomyopathy, congenital heart disease); 13. Individual with second degree and above atrioventricular block and/or sick sinus syndrome; 14. Individual with abnormal coagulation function; 15. Individual with infected waist skin; 16. Individual with malignant tumor; 17. Individual is pregnant, nursing or planning to be pregnant; 18. Individual is unwilling to sign informed consent; 19. Individual fails to complete the screening period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood pressure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jiangsu Province Hospital/The Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210000, China

  • Suzhou Municipal Hospital

    Suzhou, Jiangsu, 215000, China

  • The Affiliated Jiangning Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210000, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.